Company news
Cosciens Biopharma Inc. (TSX:CSCI) news
Cosciens Biopharma Inc. news releases on 6ix. Latest, Oct 23, 2015: Aeterna Zentaris to Announce Third Quarter 2015 Financial and Operating Results…
Press releases — page 2
Aeterna Zentaris to Announce Third Quarter 2015 Financial and Operating Results on November 6, 2015
October 23, 2015
Aeterna Zentaris Announces Special Meeting of Shareholders and Mailing of Management Information Circular
October 16, 2015
Aeterna Zentaris: Data and Safety Monitoring Board Recommends Continuation of ZoptEC Phase 3 Trial in Advanced Endometrial Cancer
October 13, 2015
Aeterna Zentaris Announces Restructuring of Finance & Accounting Operations and Closure of Quebec City Office
October 12, 2015
Aeterna Zentaris' Zoptarelin Doxorubicin Meets Phase 2 Primary Endpoint in Men with Heavily Pretreated Castration and Taxane Resistant Prostate Cancer
September 28, 2015
Aeterna Zentaris Announces TSX Approval of Series B Warrant Amendment
September 25, 2015
Aeterna Zentaris Announces Dismissal of Class Action Lawsuit
September 24, 2015
Aeterna Zentaris Announces Amendment to Series B Warrants
September 21, 2015
Aeterna Zentaris to Present at Upcoming Rodman & Renshaw Annual Global Investment Conference in New York
September 3, 2015
Aeterna Zentaris Reports Second Quarter Financial and Operating Results
August 13, 2015
Aeterna Zentaris Announces Data and Safety Monitoring Board Scheduled to Complete Second Interim Analysis of the ZoptEC Phase 3 Trial in Endometrial Cancer in Early October
August 11, 2015
Aeterna Zentaris to Announce Second Quarter 2015 Financial and Operating Results on August 13, 2015
August 6, 2015
Aeterna Zentaris to Present at Upcoming Canaccord Genuity 35th Annual Global Growth Conference in Boston
August 4, 2015
Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development
July 29, 2015
Aeterna Zentaris Grants Option to Develop and Commercialize Oral Allogenic Cancer Vaccine Technology
July 28, 2015
Aeterna Zentaris Commences Promotional Activities for EMD Serono's Saizen® [Somatropin (rDNA origin) for Injection]
July 27, 2015
Aeterna Zentaris' Confirmatory Phase 3 Study for Macrilen(TM) in AGHD Meets EMA's Study-Design Expectations
May 26, 2015
Aeterna Zentaris Announces Election of Directors at 2015 Shareholders' Meeting
May 11, 2015
Aeterna Zentaris Reports 1st Quarter 2015 Financial and Operating Results
May 7, 2015
Aeterna Zentaris and EMD Serono Finalize Promotional Services Agreement for Saizen® (Somatropin (rDNA origin) for Injection) in the U.S.
May 7, 2015
Aeterna Zentaris to Announce First Quarter 2015 Financial and Operating Results on May 7, 2015 and Hold Annual & Special Shareholders Meeting on May 8, 2015
May 1, 2015
Aeterna Zentaris: Data Safety Monitoring Board Recommends Continuation of Phase 3 Study of Zoptarelin Doxorubicin in Advanced Endometrial Cancer
April 27, 2015
Aeterna Zentaris to Present at 2015 Bloom Burton & Co. Healthcare Investor Conference in Toronto
April 23, 2015
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Aeterna Zentaris Inc.
April 23, 2015
Aeterna Zentaris Files Additional Patent Application to Strengthen IP Protection of Zoptarelin Doxorubicin
April 16, 2015
Aeterna Zentaris Announces Plans to Initiate Phase 3 Study of Macrilen(TM) in AGHD Following Successful Meeting with FDA
April 13, 2015
Aeterna Zentaris Signs Transfer Agreement of its Discovery Library with the Medical University of South Carolina
March 31, 2015
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2014 Financial and Operating Results
March 17, 2015
Aeterna Zentaris Announces Closing of US$37 Million Public Offering of Common Shares and Warrants
March 11, 2015
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2014 Financial and Operating Results on March 17, 2015
March 10, 2015
Aeterna Zentaris Announces Pricing of US$37 Million Public Offering of Common Shares and Warrants
March 6, 2015
Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants
March 5, 2015
Aeterna Zentaris to Present at Roth Conference 2015
March 2, 2015
Aeterna Zentaris to Present at Upcoming Biotech Showcase Conference in San Francisco
January 6, 2015
Aeterna Zentaris: Final Data for Phase 1 Portion of Ongoing Phase 1/2 Trial with Zoptarelin Doxorubicin in Prostate Cancer Published in Clinical Cancer Research
December 29, 2014
Aeterna Zentaris Receives Notification from NASDAQ Relating to Minimum Bid Price
December 19, 2014
Aeterna Zentaris and Sinopharm A-Think Sign Master Collaboration Agreement for Zoptarelin Doxorubicin in China
December 1, 2014
Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer
November 20, 2014
FDA Issues Complete Response Letter for Aeterna Zentaris' Macrilen(TM) NDA in Adult Growth Hormone Deficiency
November 6, 2014
/C O R R E C T I O N -- Investment Industry Regulatory Organization of Canada (IIROC) - Halts/Resumptions/
November 5, 2014
Aeterna Zentaris Reports Third Quarter 2014 Financial and Operating Results
November 4, 2014
Aeterna Zentaris to Announce Third Quarter 2014 Financial and Operating Results on November 4, 2014
October 28, 2014
Aeterna Zentaris Announces Formal Implementation of its Sales Force In Support of Selling ASCEND's EstroGel®
October 27, 2014
Aeterna Zentaris Appoints Phil Theodore as Chief Administrative Officer, General Counsel and Corporate Secretary
October 7, 2014
Aeterna Zentaris Reports Second Quarter 2014 Financial and Operating Results
August 7, 2014
Aeterna Zentaris to Present at Upcoming Canaccord Genuity 34th Annual Global Growth Conference in Boston
August 6, 2014
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
August 5, 2014
Aeterna Zentaris to Announce Second Quarter 2014 Financial and Operating Results on August 7, 2014
July 31, 2014
Aeterna Zentaris to Present at Upcoming Bloom Burton & Co. Healthcare Investor Conference in Toronto
June 11, 2014
Aeterna Zentaris Implements Global Resources Optimization Program as Part of its Transition into a Commercially Operating Specialty Biopharmaceutical Company
June 10, 2014